We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Check the tariff classification for peptide nisin standardised with sodium chloride
The MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion)
Phase II randomized trial
Fifteen additional synthetic opioids are now under the strictest controls to prevent drug related deaths and ensure anyone caught supplying them faces tough penalties.
The New Active Substance Work Sharing Initiative (NASWSI) has successfully approved several medicines through this international collaboration and continues to foster cooperation and strong relationships between its Access partners. The Biosimilar Work Sharing Initiative (BSWSI) builds on this success.
Guidance on how to license electronic cigarettes and other inhaled nicotine-containing products (NCPs) as medicines in the UK.
Fresenius Kabi Limited has informed the MHRA of an error on the infusion bag packaged into the specific batches of Sodium Chloride Intravenous Infusion 0.9% Freeflex.
Fresenius Kabi Limited have informed the MHRA of a packaging error with specific batches of Sodium Chloride Intravenous Infusion 0.9% Freeflex and Freeflex PLUS.
The government will place 6 new synthetic opioids under the strictest level of control.
This guidance covers ‘grandfathering’ and managing the lifecycle changes of medicinal products.
Marketing Authorisation Holders should review their manufacturing processes to identify and, if found, to mitigate the risk of nitrosamine impurities being present.
Fifteen new synthetic opioids and 5 other drugs will be banned as Class A drugs as the government continues to act to prevent drug deaths.
Neon Healthcare Ltd is recalling the specific batch mentioned in this notification as a precautionary measure.
Guidance to help medicine manufacturers meet safe limits on levels of nitrosamine impurities in medicines.
Product Safety Report for Innateq/Karl Schnell /KS Emulsifier F320 Type 094 presenting a serious personal injury risk due to entanglement, shearing and crushing hazards from contact with dangerous moving parts of machinery.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).